Post‐progression survival after atezolizumab plus carboplatin and etoposide as first‐line chemotherapy in small cell lung cancer has a significant impact on overall survival.
Saved in:
| Title: | Post‐progression survival after atezolizumab plus carboplatin and etoposide as first‐line chemotherapy in small cell lung cancer has a significant impact on overall survival. |
|---|---|
| Authors: | Masubuchi, Ken1 (AUTHOR), Imai, Hisao1,2 (AUTHOR) m06701014@gunma-u.ac.jp, Wasamoto, Satoshi3 (AUTHOR), Tsuda, Takeshi4 (AUTHOR), Minemura, Hiroyuki5 (AUTHOR), Nagai, Yoshiaki6 (AUTHOR), Yamada, Yutaka7 (AUTHOR), Kishikawa, Takayuki8 (AUTHOR), Umeda, Yukihiro9 (AUTHOR), Shiono, Ayako2 (AUTHOR), Takechi, Hiroki3 (AUTHOR), Shiihara, Jun6 (AUTHOR), Kaira, Kyoichi2 (AUTHOR), Kanazawa, Kenya5 (AUTHOR), Taniguchi, Hirokazu4 (AUTHOR), Kaburagi, Takayuki7 (AUTHOR), Kagamu, Hiroshi2 (AUTHOR), Minato, Koichi1 (AUTHOR) |
| Source: | Thoracic Cancer. Oct2022, Vol. 13 Issue 19, p2776-2785. 10p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
